Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series
- 1 January 1994
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 4 (1) , 29-34
- https://doi.org/10.1016/s0960-894x(01)81117-3
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Overview: Recent Advances in Angiotensin II Receptor AntagonistsCurrent Opinion on Therapeutic Patents, 1993
- Patent Update: Angiotensin-II Antagonists: Patent Activity since the Discovery of DuP-753Current Opinion on Therapeutic Patents, 1992
- The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonistMedicinal Research Reviews, 1992
- Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensivesJournal of Medicinal Chemistry, 1991
- Revised algorithms for the build‐up procedure for predicting protein conformations by energy minimizationJournal of Computational Chemistry, 1987
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- Structure-activity relationships for the competitive angiotensin antagonist [sarcosine1, O-methyltyrosine4]angiotensin II (sarmesin)Journal of Medicinal Chemistry, 1986
- A new approach to angiotensin antagonists: Methylation of the tyrosine hydroxyl in angiotensin IILife Sciences, 1984
- Script: interactive molecular geometrical treatments on the basis of computer-drawn chemical formulaTetrahedron, 1981
- Angiotensin II analogs. 12. Role of the aromatic ring of position 8 phenylalanine in pressor activityJournal of Medicinal Chemistry, 1979